Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain
Plus: BioNTech Signs Asia Deal
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
You may also be interested in...
Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.
As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.